ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Sun Pharmaceutical Industries Ltd.

  • 460.00 INR
  • -2.30
  • -0.50%
  • India
    Apr 16, 2019
  • Ticker
  • Prev. close
  • Market cap (INR)
  • Market cap (USD)
  • Shares

Business Summary

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It operates through the following geographical segments: India, United States of America, Emerging Markets, and Rest of the World. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1982 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2018 INRUSD
Gross Profit109,049.50M1,691.58M
Operating income40,954.10M635.28M
Income before tax34,789.80M539.66M
Net income21,615.50M335.30M
Diluted EPS90.13
Dividends Per Share20.03
Total Assets649,909.70M9,964.62M
Total liabilities230,062.50M3,527.39M
Total equity381,005.60M5,841.70M
Operating cash flow39,781.60M617.09M
Currency in INRCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 160,043.90M 272,865M 281,086.10M 313,081.40M 264,155.40M
Gross Profit 102,872.40M 140,261.50M 149,951.40M 158,651.20M 109,049.50M
Operating income 69,559.90M 68,831.20M 75,140.60M 84,884.50M 40,954.10M
Income before tax 45,830.90M 64,029M 65,706.30M 90,478.70M 34,789.80M
Net income 31,433.90M 45,393.80M 45,457.10M 69,643.70M 21,615.50M
EBITDA 73,652.20M 80,778.40M 85,515.90M 97,532M 55,952.50M
Diluted EPS 15.20 18.90 18.90 29 9
Dividends Per Share 1.50 3 1 3.50 2
Total Assets 293,841M 494,235.80M 559,415.90M 619,117.90M 649,909.70M
Total liabilities 89,379.70M 209,343M 188,572.10M 214,674.70M 230,062.50M
Total equity 185,249.50M 256,231.90M 329,824.80M 366,396.70M 381,005.60M
Operating cash flow 41,341.80M 53,591.20M 67,726.30M 71,269.50M 39,781.60M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 2,648.23M 4,462.70M 4,293.30M 4,668.88M 4,097.58M
Gross Profit 1,702.22M 2,293.97M 2,290.35M 2,365.91M 1,691.58M
Operating income 1,151.00M 1,125.73M 1,147.69M 1,265.85M 635.28M
Income before tax 758.35M 1,047.19M 1,003.59M 1,349.27M 539.66M
Net income 520.13M 742.41M 694.31M 1,038.57M 335.30M
EBITDA 1,218.71M 1,321.12M 1,306.16M 1,454.46M 867.93M
Diluted EPS 0.25 0.30 0.28 0.43 0.13
Dividends Per Share 0.02 0.04 0.01 0.05 0.03
Total Assets 4,920.10M 7,897.50M 8,447.51M 9,534.42M 9,964.62M
Total liabilities 1,496.58M 3,345.13M 2,847.55M 3,305.99M 3,527.39M
Total equity 3,101.83M 4,094.38M 4,980.55M 5,642.51M 5,841.70M
Operating cash flow 684.07M 876.48M 1,034.44M 1,062.81M 617.09M

Valuation Measures

Mar 2018
Operating margin15.50%
Profit margin8.18%

Key executives

  • Managing Director & Executive Director: Dilip Shantilal Shanghvi
  • Chief Financial Officer: C. S. Muralidharan
  • Compliance Officer & Senior GM-Secretarial: Ashok I. Bhuta
  • Vice President & Global Head-Regulatory: Rajeev S. Mathur
  • Senior Vice President-Business Development: Kirti Wardhaman Ganorkar


  • Life Insurance Corp. of India (5.9%)
  • ICICI Prudential Asset Management Co. Ltd. (3.5%)
  • Aditya Medisales Ltd. (1.6%)
  • The Vanguard Group, Inc. (1.5%)
  • Lakshdeep Investments & Finance Pvt Ltd. (1.4%)
  • GIC Pte Ltd. (Investment Management) (1.3%)
  • Reliance Nippon Life Asset Management Ltd. (Invt Mgmt) (1.2%)

Contact Details

  • Website:
  • Address: CTS No. 201 B/1, Sun House, Western Express Highway, Mumbai, 400063, India
  • Phone: +91.22.43244324

Related Companies

  • Sun Pharmaceuticals Germany GmbH
  • Sun Pharmaceuticals Morocco LLC Sarlau
  • Sun Pharma Netherlands BV
  • Sun Pharmaceutical Industries (Australia) Pty Ltd.
  • Ocular Technologies SARL
  • Sun Pharmaceutical Industries Ltd. /7 Brands/
  • Sun Pharmaceutical Industries Ltd. /Bryan Ops/
  • GlaxoSmithKline Plc /Opiates Business/
  • Sun Pharma Laboratories Ltd.
  • Sun Global Canada Pty Ltd.
  • Sun Pharmaceutical Industries Europe BV
  • Aditya Acquisition Co. Ltd.
  • SPIL de Mexico SA de CV
  • Sun Pharma de Mexico SA de CV
  • Tamil Nadu Dadha Pharmaceuticals Ltd.
  • Pradeep Drug Co. Ltd.
  • Pola Pharma, Inc.
  • Ranbaxy
  • Pharmalucence, Inc.
  • Alkaloida Chemical Co. Exclusive Group Ltd.
  • Sun Pharmaceutical Industries Key Employees Benefit Trust
  • Sun Pharmaceutical Industries, Inc.
  • Chattem Chemicals, Inc.
  • Generic Pharmaceutical Co.
  • Zenotech Laboratories Limited
  • MJ Pharmaceuticals Ltd. /Manufacturing Business/
  • MJ Pharmaceuticals Pvt Ltd.
  • Phlox Pharmaceuticals Ltd.
  • Hindustan Antibiotics Ltd.
  • Gujarat Lyka Organics Ltd


  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited
  • Glenmark Pharmaceuticals Limited
  • IPCA Laboratories Limited
  • Wockhardt Limited
  • FDC Ltd.
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd
  • Cadila Healthcare Limited
  • ANI Pharmaceuticals, Inc.
  • Zentiva SA
  • Cytori Therapeutics, Inc.
  • Antares Pharma, Inc.
  • Amneal Pharmaceuticals, Inc. Class A
  • Kala Pharmaceuticals, Inc.
  • Aerie Pharmaceuticals, Inc.
  • Nicox SA
  • Sienna Biopharmaceuticals, Inc.
  • Cumberland Pharmaceuticals Inc.
  • Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A
  • Curis, Inc.
  • TPI Enterprises Ltd.
  • Acura Pharmaceuticals, Inc.
  • BioPharmX Corp.
  • Evolus, Inc.
  • Intec Pharma Ltd
  • Sol-Gel Technologies Ltd.
Last Updated on 16 Apr, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends April 19th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media